Freepik.comAlzheimer’s disease means memory loss for those affected. Beyond this, however, it is above all relatives and care staff who are impacted when the loss of cognitive abilities is accompanied by symptoms such as agitation, aggression, anxiety and depression, making home care impossible. This aspect of the disease is now gaining greater visibility through a major second financing round from EQT LifeScience, Gimv and Andera Partners with Exciva from Heidelberg.
Tag Archive for: Gimv
ImmunOs Therapeutics AG Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.